ATP6V1C2

Across TCGA pan-cancer cohorts, ATP6V1C2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP6V1C2 data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ATP6V1C2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ATP6V1C2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LUAD, and LUSC are the cancer types where ATP6V1C2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.797	0.633	.012	30	view →
LUAD	OS	Median	II,III,IV	0.187	0.711	<.001	27	view →
LUSC	OS	Median	All	0.080	0.776	<.001	24	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATP6V1C2–UCEC (DFS)

Open the UCEC breakdown →